Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Epcoritamab by Genmab for Refractory Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
Epcoritamab is under clinical development by Genmab and currently in Phase II for Refractory Chronic Lymphocytic Leukemia (CLL). According to...
Epcoritamab by Genmab for Burkitt Lymphoma: Likelihood of Approval
Epcoritamab is under clinical development by Genmab and currently in Phase I for Burkitt Lymphoma. According to GlobalData, Phase I...
Epcoritamab by Genmab for Non-Hodgkin Lymphoma: Likelihood of Approval
Epcoritamab is under clinical development by Genmab and currently in Phase I for Non-Hodgkin Lymphoma. According to GlobalData, Phase I...
GEN-1184 by Genmab for Fallopian Tube Cancer: Likelihood of Approval
GEN-1184 is under clinical development by Genmab and currently in Phase II for Fallopian Tube Cancer. According to GlobalData, Phase...
GEN-3017 by Genmab for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma): Likelihood of Approval
GEN-3017 is under clinical development by Genmab and currently in Phase II for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma). According to...
Tisotumab vedotin by Genmab for Fallopian Tube Cancer: Likelihood of Approval
Tisotumab vedotin is under clinical development by Genmab and currently in Phase II for Fallopian Tube Cancer. According to GlobalData,...
Tisotumab vedotin by Genmab for Recurrent Head And Neck Squamous Cell Carcinoma: Likelihood of Approval
Tisotumab vedotin is under clinical development by Genmab and currently in Phase II for Recurrent Head And Neck Squamous Cell...
Tisotumab vedotin by Genmab for Metastatic Colorectal Cancer: Likelihood of Approval
Tisotumab vedotin is under clinical development by Genmab and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData,...
Tisotumab vedotin by Genmab for Esophageal Cancer: Likelihood of Approval
Tisotumab vedotin is under clinical development by Genmab and currently in Phase II for Esophageal Cancer. According to GlobalData, Phase...
GEN-3014 by Genmab for Diffuse Large B-Cell Lymphoma: Likelihood of Approval
GEN-3014 is under clinical development by Genmab and currently in Phase II for Diffuse Large B-Cell Lymphoma. According to GlobalData,...
GEN-3014 by Genmab for Refractory Acute Myeloid Leukemia: Likelihood of Approval
GEN-3014 is under clinical development by Genmab and currently in Phase II for Refractory Acute Myeloid Leukemia. According to GlobalData,...
Tisotumab vedotin by Genmab for Solid Tumor: Likelihood of Approval
Tisotumab vedotin is under clinical development by Genmab and currently in Phase II for Solid Tumor. According to GlobalData, Phase...
Tisotumab vedotin by Genmab for Bladder Cancer: Likelihood of Approval
Tisotumab vedotin is under clinical development by Genmab and currently in Phase II for Bladder Cancer. According to GlobalData, Phase...
Tisotumab vedotin by Genmab for Pancreatic Cancer: Likelihood of Approval
Tisotumab vedotin is under clinical development by Genmab and currently in Phase II for Pancreatic Cancer. According to GlobalData, Phase...
Tisotumab vedotin by Genmab for Ovarian Cancer: Likelihood of Approval
Tisotumab vedotin is under clinical development by Genmab and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase...
Tisotumab vedotin by Genmab for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
Tisotumab vedotin is under clinical development by Genmab and currently in Phase II for Head And Neck Squamous Cell Carcinoma...
Tisotumab vedotin by Genmab for Epithelial Ovarian Cancer: Likelihood of Approval
Tisotumab vedotin is under clinical development by Genmab and currently in Phase II for Epithelial Ovarian Cancer. According to GlobalData,...
Tisotumab vedotin by Genmab for Peritoneal Cancer: Likelihood of Approval
Tisotumab vedotin is under clinical development by Genmab and currently in Phase II for Peritoneal Cancer. According to GlobalData, Phase...
GEN-3014 by Genmab for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
GEN-3014 is under clinical development by Genmab and currently in Phase II for Relapsed Acute Myeloid Leukemia. According to GlobalData,...
Tisotumab vedotin by Genmab for Endometrial Cancer: Likelihood of Approval
Tisotumab vedotin is under clinical development by Genmab and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase...